John Mulhall, MD
Urology · New York, NYNPI 1205813623
Payments from drug & device makers
Across 47 payments — averaging $770.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Inc.$21K
- Endo Pharmaceuticals Inc.$8K
- Endo USA, Inc.$4K
- Astellas Pharma Inc$2K
- Coloplast$632
- Mylan Pharmaceuticals Inc.$408
- plus $709 from 3 others
Across 2 payments — averaging $209.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$419
What the payments were for
- Consulting fees$20,22062%
- Speaking & faculty fees$4081%
- Travel & lodging$9,20528%
- Food & beverage$2,7799%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Inc. | 13 | $20,719 |
| Endo Pharmaceuticals Inc. | 12 | $7,740 |
| Endo USA, Inc. | 5 | $4,004 |
| Astellas Pharma Inc | 1 | $2,000 |
| Coloplast | 7 | $632 |
| Mylan Pharmaceuticals Inc. | 1 | $408 |
| Boston Scientific | 2 | $285 |
| Axogen | 2 | $224 |
| Antares Pharma, Inc. | 4 | $200 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,212 in reported general payments places this provider in the 85th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone Cypionate | 22 | $918 |
Paid to pharmacies, not to this prescriber.
Other urology in New York
- Guarionex DecastroNew York$5.7M
- James McKiernanNew York$4.1M
- William HuangNew York$3.9M
- Ashutosh TewariNew York$2.5M
- Bilal ChughtaiNew York$1.5M
- Nils Peter WiklundNew York$1M
- Herbert LeporNew York$823K
- Christopher AndersonNew York$785K
- Katie MurrayNew York$776K
- John SfakianosNew York$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.